FDA Reaffirms Safety of Nuplazid® (pimavanserin) to Treat PD Psychosis
- Brooks, M. FDA Reaffirms Safety of Pimavanserin in PD Psychosis – Medscape. Published September 21, 2018. https://www.medscape.com/viewarticle/902334. Accessed online September 24, 2018.
- FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis. Published September 20, 2018. https://www.businesswire.com/news/home/20180920005948/en/FDA-Issues-Statement-Reaffirming-Positive-Benefit-Risk-Profile. Accessed online September 26, 2018.
- Minton, LS. Pontone,G. Perepezko, K. Psychosis: A Mind Guide to Parkinson’s disease. Parkinson’s Foundation. Updated 2018. https://www.parkinson.org/sites/default/files/attachments/Psychosis.pdf. Accessed online September 27, 2018.
- FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis. FDA website. Published September 20, 2018. https://www.fda.gov/Drugs/DrugSafety/ucm621160.htm. Accessed online September 25, 2018.